Novo Nordisk A/S (NYSE:NVO) Trading Down 0.7% - Should You Sell?

Novo Nordisk A/S (NYSE:NVO - Get Free Report)'s stock price traded down 0.7% on Tuesday . The company traded as low as $74.57 and last traded at $74.80. 2,005,473 shares changed hands during trading, a decline of 63% from the average session volume of 5,430,226 shares. The stock had previously closed at $75.33.

Wall Street Analysts Forecast Growth

NVO has been the topic of several research reports. BMO Capital Markets lowered their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an "outperform" rating on the stock in a research report on Monday, December 23rd. BNP Paribas upgraded Novo Nordisk A/S to a "strong-buy" rating in a research report on Monday, December 2nd. UBS Group upgraded Novo Nordisk A/S from a "sell" rating to a "buy" rating in a research report on Wednesday, January 8th. Morgan Stanley assumed coverage on Novo Nordisk A/S in a report on Wednesday, February 12th. They set an "equal weight" rating on the stock. Finally, Kepler Capital Markets raised Novo Nordisk A/S from a "hold" rating to a "buy" rating in a report on Thursday, March 13th. Three research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. Based on data from MarketBeat.com, the stock has a consensus rating of "Moderate Buy" and a consensus price target of $145.25.

Novo Nordisk A/S Stock Performance

The company has a 50-day moving average of $82.33 and a 200 day moving average of $99.11. The firm has a market capitalization of $311.23 billion, a PE ratio of 21.08, a PEG ratio of 0.90 and a beta of 0.42. The company has a quick ratio of 0.55, a current ratio of 0.74 and a debt-to-equity ratio of 0.62.

Remove Ads

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its quarterly earnings data on Wednesday, February 5th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.88 by $0.03. Novo Nordisk A/S had a net margin of 34.81% and a return on equity of 84.68%. Equities research analysts predict that Novo Nordisk A/S will post 3.84 EPS for the current year.

Novo Nordisk A/S Increases Dividend

The business also recently announced a semi-annual dividend, which will be paid on Tuesday, April 8th. Investors of record on Monday, March 31st will be given a $0.7874 dividend. The ex-dividend date is Monday, March 31st. This is a positive change from Novo Nordisk A/S's previous semi-annual dividend of $0.51. This represents a yield of 1.2%. Novo Nordisk A/S's payout ratio is 47.72%.

Institutional Investors Weigh In On Novo Nordisk A/S

A number of large investors have recently added to or reduced their stakes in NVO. Center for Financial Planning Inc. raised its holdings in shares of Novo Nordisk A/S by 72.4% during the 4th quarter. Center for Financial Planning Inc. now owns 293 shares of the company's stock valued at $25,000 after buying an additional 123 shares in the last quarter. Strategic Investment Solutions Inc. IL grew its position in Novo Nordisk A/S by 2,727.3% during the fourth quarter. Strategic Investment Solutions Inc. IL now owns 311 shares of the company's stock valued at $27,000 after acquiring an additional 300 shares during the last quarter. Daiwa Securities Group Inc. purchased a new position in shares of Novo Nordisk A/S during the third quarter worth approximately $28,000. Park Square Financial Group LLC bought a new stake in shares of Novo Nordisk A/S in the 4th quarter worth approximately $29,000. Finally, Transce3nd LLC purchased a new stake in shares of Novo Nordisk A/S in the 4th quarter valued at $33,000. Hedge funds and other institutional investors own 11.54% of the company's stock.

Novo Nordisk A/S Company Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.